secwatch.observer — SEC 8-K summary
======================================

Issuer:     GridAI Technologies Corp. (GRDX)
CIK:        0001604191
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001104659-25-027770
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO
--------------------------------------------------------------------------------

- Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.
- Closing conditions include shareholder approval by June 30, 2025, lender consent, and resignation of director Jack Syage.
- Company retains ~$695,000 of ImmunogenX accounts payable; ImmunogenX remains responsible for ~$9.28M secured debt.
- Anna Skowron appointed CFO effective March 3, 2025; brings 14+ years of accounting and financial reporting experience.
- CEO states rescission strengthens balance sheet and refocuses value creation strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/0001104659-25-027770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604191/000110465925027770/tm2510211d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-027770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer